OctoPlus announces the proposal to appoint Catherine Moukheibir to the Supervisory Board
(Thomson Reuters ONE) -
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO) announces today
that the Supervisory Board of the Company will nominate Catherine Moukheibir to
be appointed as member of the Supervisory Board at the next General Meeting of
Shareholders. This appointment will be for a period of four years.
Catherine Moukheibir MA, MBA, age 52, was CFO of Movetis, a Belgian specialty
pharmaceutical company from 2008 to 2010, for which she led the IPO on Euronext
Brussels and subsequently the acquisition by Shire. Previously, she was Director
Capital Markets at Zeltia (from 2001 to 2007), a Spanish biopharma and consumer
chemicals group, where she led financial strategy. Before joining Zeltia, she
was Executive Director Investment Banking with Salomon Smith Barney and Morgan
Stanley (from 1997 to 2000). Catherine Moukheibir is currently Senior Advisor
Finance and member of the Executive Board of Innate Pharma S.A. and is
responsible for their financial strategy.
The Supervisory Board also announces that Hans Stellingsma has informed the
Board of his decision to resign from the Supervisory Board to pursue other
opportunities outside the Company due to personal reasons, effectively April
15. As mentioned in a previous announcement, the Supervisory Board proposes to
appoint Dr. Staf van Reet, Ph.D., as the new Chairperson of the Supervisory
Board at the upcoming Annual General Meeting of Shareholders.
Jan Egberts, CEO of OctoPlus: "We are delighted about the nomination of
Catherine as a member of our Supervisory Board. With her extensive financial
experience and personal network within the healthcare and finance industry she
is extremely well positioned to help OctoPlus transition to our next phase. I
would also like to use this opportunity to thank Hans for his efforts over the
past 10 years.
For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071, or
send an e-mail to Investor Relations at IR(at)octoplus.nl.
About OctoPlus
OctoPlus is a specialty pharmaceutical company focused on the development and
manufacture of improved injectable pharmaceuticals based on our proprietary drug
delivery technologies that exhibit fewer side effects, improved patient
convenience and a better efficacy/safety balance than existing therapies.
OctoPlus also focuses on the development of long-acting, controlled release
versions of known protein therapeutics, peptides and small molecules, including
specialty generics.
The clinically most advanced product incorporating our technology is
Locteron(®), a controlled release formulation of interferon alpha for the
treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to
Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus
and has completed Phase IIb clinical studies with superior clinical data versus
current treatment.
In addition, OctoPlus is a leading European provider of advanced drug
formulation and clinical scale manufacturing services to the pharmaceutical and
biotechnology industries, with a focus on difficult-to-formulate active
pharmaceutical ingredients.
OctoPlus is listed on NYSE Euronext in Amsterdam under the symbol OCTO. For more
information about OctoPlus, please visit our website www.octoplus.nl.
This document may contain certain forward-looking statements relating to the
business, financial performance and results of the Company and the industry in
which it operates. These statements are based on OctoPlus N.V.'s current plans,
estimates and projections, as well as its expectations of external conditions
and events. In particular the words "expect", "anticipate", "predict",
"estimate", "project", "plan", "may", "should", "would", "will", "intend",
"believe" and similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors, and the
inherent risks and uncertainties that such statements involve, could cause
actual results or outcomes to differ materially from those expressed in any
forward-looking statements. In the event of any inconsistency between an English
version and a Dutch version of this document, the English version will prevail
over the Dutch version.
Click here for the press release in PDF format:
http://hugin.info/137076/R/1602537/506377.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: OctoPlus N.V. via Thomson Reuters ONE
[HUG#1602537]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="RAK Marine in talks to acquire an oil and gas distribution companyDatum: 16.04.2012 - 07:30 Uhr
Sprache: Deutsch
News-ID 134978
Anzahl Zeichen: 5555
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 178 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"OctoPlus announces the proposal to appoint Catherine Moukheibir to the Supervisory Board"
steht unter der journalistisch-redaktionellen Verantwortung von
OctoPlus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
